New drug aimed at reversing fatty liver disease shows promise in trial
NCT ID NCT04104321
First seen Feb 25, 2026 · Last updated May 23, 2026 · Updated 14 times
Summary
This study tests a drug called Aramchol in people with nonalcoholic steatohepatitis (NASH), a serious liver condition linked to obesity and diabetes. The goal is to see if Aramchol can reduce liver scarring and improve liver health. About 150 adults with confirmed NASH and moderate liver scarring took part. The trial was paused due to COVID-19, with final results expected in 2027.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NONALCOHOLIC STEATOHEPATITIS (NASH) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Texas Clinical Research Institute, LLC
Arlington, Texas, 76012, United States
-
The Public Health Trust of Miami-Dade County, Florida, dba the Jackson Health System
Miami, Florida, 33136, United States
Conditions
Explore the condition pages connected to this study.